Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
READY: Dasatinib + Docetaxel in Castration-Resistant Prostate Cancer
NCT00744497Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2008
- Primary completion
- Aug 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 25
01
Overview
A Phase 3 trial of dasatinib in prostate cancer (PCa), sponsored by Bristol Myers Squibb. Started Oct 2008; status: completed.
02
Drugs
dasatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00744497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00744497.